Show simple item record

 
dc.contributorConsorci Sanitari de Terrassa
dc.contributor.authorGrau, Marta
dc.contributor.authorLópez, Cristina
dc.contributor.authorNavarro, Alba
dc.contributor.authorFrigola, Gerard
dc.contributor.authorNadeu, Ferran
dc.contributor.authorClot, Guillem
dc.contributor.authorVicente Folch, Laura
dc.date.accessioned2023-08-25T12:09:16Z
dc.date.available2023-08-25T12:09:16Z
dc.date.issued2023-07-25
dc.identifier.citationGrau M, López C, Navarro A, Clot G, Frigola G, Nadeu F, et al. Unraveling the genetics of transformed splenic marginal zone lymphoma. Blood Adv. 2023 Jul 25;7(14):3695-3709.
dc.identifier.urihttps://hdl.handle.net/11351/10163
dc.descriptionLeukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Cell, Diffuse; Mutation
dc.description.abstractThe genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P = .001; P = .042; and P = .007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event.
dc.language.isoeng
dc.publisherAmerican Society of Hematology
dc.relation.ispartofseriesBlood Advances;7(14)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectLeucèmia limfocítica crònica
dc.subjectLimfomes
dc.subjectMutació (Biologia)
dc.subject.meshLeukemia, Lymphocytic, Chronic, B-Cell
dc.subject.meshLymphoma, Large B-Cell, Diffuse
dc.subject.meshMutation
dc.titleUnraveling the genetics of transformed splenic marginal zone lymphoma
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1182/bloodadvances.2022009415
dc.subject.decsleucemia linfocítica crónica de células B
dc.subject.decslinfoma de células B grandes difuso
dc.subject.decsmutación
dc.relation.publishversionhttps://doi.org/10.1182/bloodadvances.2022009415
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Grau M] Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [López C, Navarro A, Clot G] Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Universitat de Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. [Frigola G] Hematopathology Section, Department of Pathology, Hospital Clínic de Barcelona, Barcelona, Spain. [Nadeu F] Molecular Pathology of Lymphoid Neoplasms, Fundació Clínic per a la Recerca Biomèdica - Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. [Vicente Folch L] Servei d’Hematologia, Hospital de Terrassa, Consorci Sanitari de Terrassa, Terrassa, Spain
dc.identifier.pmid36995085
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record